BRPI0808035A2 - uso de inibidores da degradação de p27, em particular argirina e derivados da mesma, para o tratamento de doenças proliferativas. - Google Patents
uso de inibidores da degradação de p27, em particular argirina e derivados da mesma, para o tratamento de doenças proliferativas.Info
- Publication number
- BRPI0808035A2 BRPI0808035A2 BRPI0808035A BRPI0808035A BRPI0808035A2 BR PI0808035 A2 BRPI0808035 A2 BR PI0808035A2 BR PI0808035 A BRPI0808035 A BR PI0808035A BR PI0808035 A BRPI0808035 A BR PI0808035A BR PI0808035 A2 BRPI0808035 A2 BR PI0808035A2
- Authority
- BR
- Brazil
- Prior art keywords
- argirine
- derivatives
- treatment
- proliferative diseases
- degradation inhibitors
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07004185A EP1964560A1 (en) | 2007-02-28 | 2007-02-28 | Use of inhibitors of the degradation of p27 for the treatment of cancer |
| EP07004185.0 | 2007-02-28 | ||
| US96593207P | 2007-08-22 | 2007-08-22 | |
| US60/965,932 | 2007-08-22 | ||
| PCT/EP2008/001552 WO2008104387A1 (en) | 2007-02-28 | 2008-02-27 | Use of inhibitors of the degradation of p27, in particular argyrin and derivatives thereof, for the treatment of proliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0808035A2 true BRPI0808035A2 (pt) | 2017-05-02 |
| BRPI0808035B1 BRPI0808035B1 (pt) | 2020-11-17 |
| BRPI0808035B8 BRPI0808035B8 (pt) | 2021-05-25 |
Family
ID=38863411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0808035A BRPI0808035B8 (pt) | 2007-02-28 | 2008-02-27 | uso de inibidores da degradação de p27 para o tratamento de câncer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8217071B2 (pt) |
| EP (2) | EP1964560A1 (pt) |
| JP (1) | JP5564267B2 (pt) |
| AU (1) | AU2008220967B2 (pt) |
| BR (1) | BRPI0808035B8 (pt) |
| CA (1) | CA2679435C (pt) |
| ES (1) | ES2396115T3 (pt) |
| WO (1) | WO2008104387A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138507A1 (en) | 2008-06-23 | 2009-12-30 | Helmholtz-Zentrum für Infektionsforschung GmbH | Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles |
| GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| US8853249B2 (en) | 2009-12-14 | 2014-10-07 | Helmholtz-Zentrum für Infektionsforschungs GmbH | Method for producing intermediates for the production of macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| GB2367553A (en) * | 2000-09-04 | 2002-04-10 | Novartis Ag | Pharmaceutically Active Macrocycles |
| AU2002243477B2 (en) * | 2001-01-05 | 2007-12-20 | New York University | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
| US20060035280A1 (en) * | 2004-01-15 | 2006-02-16 | Kuo-Sen Huang | Screening methods for inhibitors of protein-protein binding interactions |
-
2007
- 2007-02-28 EP EP07004185A patent/EP1964560A1/en not_active Withdrawn
-
2008
- 2008-02-27 JP JP2009551133A patent/JP5564267B2/ja active Active
- 2008-02-27 BR BRPI0808035A patent/BRPI0808035B8/pt active IP Right Grant
- 2008-02-27 CA CA2679435A patent/CA2679435C/en active Active
- 2008-02-27 WO PCT/EP2008/001552 patent/WO2008104387A1/en active Application Filing
- 2008-02-27 US US12/527,428 patent/US8217071B2/en active Active
- 2008-02-27 EP EP08716083A patent/EP2120929B1/en active Active
- 2008-02-27 ES ES08716083T patent/ES2396115T3/es active Active
- 2008-02-27 AU AU2008220967A patent/AU2008220967B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008220967B2 (en) | 2013-03-21 |
| EP2120929A1 (en) | 2009-11-25 |
| EP2120929B1 (en) | 2012-09-26 |
| ES2396115T3 (es) | 2013-02-19 |
| US8217071B2 (en) | 2012-07-10 |
| BRPI0808035B1 (pt) | 2020-11-17 |
| WO2008104387A1 (en) | 2008-09-04 |
| US20100144822A1 (en) | 2010-06-10 |
| CA2679435A1 (en) | 2008-09-04 |
| BRPI0808035B8 (pt) | 2021-05-25 |
| EP1964560A1 (en) | 2008-09-03 |
| CA2679435C (en) | 2016-07-12 |
| JP5564267B2 (ja) | 2014-07-30 |
| AU2008220967A1 (en) | 2008-09-04 |
| JP2010519323A (ja) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120741T1 (el) | Θεραπεια οζωδους σκληρυνσης | |
| BRPI0814267A2 (pt) | Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico. | |
| BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
| BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
| BRPI0810523A2 (pt) | Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos. | |
| BRPI0818426A2 (pt) | produto de combinação, uso de um produto de combinação, e, método para tratar câncer | |
| BRPI0813156A2 (pt) | Haste intramedular com prendedor pivotante e método para uso da mesma | |
| BRPI0810524A2 (pt) | Derivado de (aza)indol e uso do mesmo para propósitos médicos | |
| BRPI0807717A2 (pt) | Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas. | |
| DK2049525T3 (da) | N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf | |
| BRPI0819819A2 (pt) | Preparações, método e kits ùteis para o tratamento de tosse | |
| BRPI0813828A2 (pt) | Compostos antimicrobianos, a síntese dos mesmos e o uso dos mesmos para o tratamento de infecções em mamíferos | |
| BRPI0810208A2 (pt) | Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer. | |
| BRPI0812944A2 (pt) | Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids | |
| BRPI0907572A2 (pt) | Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos | |
| BRPI0814529A2 (pt) | Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central. | |
| BRPI0914863A2 (pt) | formulação tópica estável, e, uso da mesma | |
| BRPI0615163A2 (pt) | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 | |
| BRPI0818459A2 (pt) | Composição farmacêutica adequada para uso oftálmico. | |
| BRPI0719345A2 (pt) | Di-hidroimidazóis substituídos e seu uso no tratamento de tumores. | |
| BRPI0909314A2 (pt) | Composição hericida, uso da mesma, método para controlar vegetação indesejável, e, formulação herbicida. | |
| FR2915199B1 (fr) | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. | |
| BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
| DK1773796T3 (da) | Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf | |
| BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |